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Abstract A procedure for the iodoamination of unfunctionalized olefins tethered to a tosyl-protected 
NH-group has been developed. The combined use of KI and H2O2 in aqueous medium was effective for 
the preparation of iodomethyl-substituted nitrogen-containing heterocycles. The selective exo-trig 
iodocyclization provided 1,2-bifunctional 5-, 6-, and 7-membered cyclic skeletons. 
 
 
 
Introduction 
The development of efficient synthetic protocols which allow the formation of more than one bond 
in a single step plays a central role in organic synthesis. Recently, haloamination of carbon-carbon 
double bond involving an intramolecular carbon-nitrogen bond formation received great attention as 
fruitful methodology for the synthesis of nitrogen-containing heterocycles.[1-3] The usefulness of 
heterocycles containing a vicinal haloamine moiety as versatile synthetic intermediates[4-7] or as 
potential medicinal agents[8,9] is well established. 
Among the alkene halocyclizations, iodoamination reactions represent a powerful tool for the 
preparation of heterocycles suitable for further introduction of functionalities.[10,11] The formation of a 
carbon-iodine bond provides high added value to the process as proven by the multi-faceted conversions 
which can undergo. While the most efficient procedures for the access to vicinal chloro- and 
bromoamines are based on transition metal-catalyzed reactions, direct formation of vicinal iodoamines 
from aminoalkenes can be typically realized by initial activation of the carbon-carbon double bond with 
different sources of electrophile. Molecular iodine and N-iodosuccinimide (NIS) have been widely used 
with amide-type substrates (Scheme 1a)[12-15] as well as with alkenyl imidates (Scheme 1b).[16-18] 
Alternatively, KI in the presence of a hypervalent iodine derivatives (Scheme 1c)[19] or a transition 
metal-catalyst (Scheme 1d)[20-21]  were proven to be effective for this goal. Also NaI, combined with 
MnI2 as catalyst, has been proven a useful source of iodine for iodoamination of unfunctionalized olefins 
(Scheme 1e).[22-23]  It is worth noting also the iodocyclization of alkenyl carbamates performed with 
Bu4NI as iodine source with NaNO2 as catalyst and molecular oxygen as oxidant.
[24] 
 The importance of the development of a mild and easy synthesis of vicinal iodoamine moieties is 
also due to their role as core scaffolds in various structures of bioactive compounds. In particular, some 
antitumor, anti-infective, and anti-inflammatory agents feature iodomethyl substituted nitrogen-
containing heterocycles (Figure 1).[25-26] 
 
 
Scheme 1. Synthetic procedure for aminoiodination 
Following our previous investigations on heterocyclization reactions in domino processes,[27-30]  we 
focused our attention on the search of alternative conditions for intramolecular amination reactions 
combined with iodine functionalization (Scheme 1f). Herein we report selected mild conditions relying 
 on the use of KI as iodine source and H2O2 as oxidant agent which act in water at room temperature 
providing iodomethyl-substituted heterocycles. Although it is known that H2O2 has been used 
combined to tetrabutylammonium iodide to promote an amination reaction,[31]  to the best of our 
knowledge the possibility to perform iodoamination reactions by the use of KI/H2O2 is unknown in the 
literature.  
 
Figure 1. Selected bioactive vicinal iodoamine derivatives 
 
Results and Discussion 
O-Allyl-N-tosylcarbamate (1a) was investigated in preliminary experiments aimed to explore new 
conditions for the feasibility of the iodoamination reaction. Various combinations of iodine sources and 
oxidant agents in different solvents used to afford the oxazolidinone product 2a are collected in Table 
1. A stoichiometric amount of molecular iodine or NIS in acetonitrile at room temperature furnished the 
iodoamination product in unsatisfactory yields in a complex crude mixture, in the latter case also due to 
the formation of the O-(2,3-diiodopropyl)-N-tosyl-carbamate (Table 1, entries 1 and 2). The same 
acyclic diiodinated compound was obtained as by-product when the reaction was carried out in the 
presence of NIS and CuCl2 as the oxidant in oxygen atmosphere (Table 1, entry 3). A iodocyclizative 
process was observed when I2 and NIS were combined with PIFA, although the product resulted in the 
3-unsubstituted 4-iodomethyloxazolidinone, isolated in both cases in moderate yields (Table 1, entries 
4 and 5). Conversely, the use of PIFA was effective if used with KI as iodine source, providing 2a in 
81% yield (Table 1, entry 6). 
 Other hypervalent iodine derivatives such as PIDA and PhI(mcba)2 were a good choice as promoter 
to afford 2a, although with a slight decrease in yield (Table 1, entries 7 and 8). Following these 
preliminary results, we focused on other conditions based on the presence of KI as iodine source. Using 
molecular iodine in O2 atmosphere combined with benzoquinone as further oxidant in acetonitrile, no 
formation of 2a was observed and carbamate 1a was completely recovered (Table 1, entry 9). Also 
MnO2 was tested as additive in the reaction mixture under oxygen atmosphere but 2a was achieved in 
low yield (Table 1, entry 10). Intriguingly, a consistent improvement of the outcome of the reaction was 
detected when H2O2 was used as the sole oxidant in the presence of KI and CH3CN as the solvent. These 
conditions determined a neat conversion of 1a, providing the desired iodoamination product in 79% 
yield (Table 1, entry 11). Use of DMF or dioxane led to a remarkable decrease of the yield (Table 1, 
entries 12 and 13), while water associated to DMSO or CH3CN as a co-solvent was gratifyingly proven 
to be a good medium to obtain the complete conversion of the substrate into 2a in mild conditions (Table 
1, entries 14 and 15). Working in the conditions of Table 1, entry 14, the crude mixture resulted cleaner 
than the corresponding reaction carried out with I2 or NIS as iodine source. Besides, the product obtained 
might be collected through an easy filtration, due to its lower solubility in the DMSO/H2O mixture 
compared to the starting material. 
 
Table 1. Optimization of the reaction conditions.  
 
Entry Iodine 
source 
Oxidant 
 
Solvent[a] Time 
(h) 
2a[b] 
(% 
yield) 
1 I2 - CH3CN 30 52 
2 NIS - CH3CN 18 29[
c] 
3[d] NIS  CuCl2 (5 mol%), O2 CH3CN 24 49[
c] 
4 I2 PIFA  CH3CN 4 -[
e] 
5 NIS  PIFA  CH3CN 6  -[
e] 
6 KI  PIFA CH3CN 3 81  
7 KI PIDA CH3CN 8 68 
8 KI  PhI(mcba)2  CH3CN 20 73  
9 KI BQ (20 mol%), O2 CH3CN 48 - 
10 KI  MnO2 (20 mol%), O2 CH3CN 48 31 
11[f] KI  H2O2  CH3CN 24 79 
 12[f] KI  H2O2 DMF 24 32 
13[f] KI H2O2  Dioxane 24 54 
14[f] KI H2O2  H2O/ 
DMSO[g] 
24 78 
15[f] KI H2O2  H2O/CH3CN[
h] 24 67 
[a] The reactions were carried out at room temperature unless otherwise stated. [b] 
Yields of purified products. [c] O-(2,3-Diiodopropyl)-N-tosyl-carbamate has been 
isolated in 57% yield (entry 2) and 37% yield (entry 3). [d] The reaction was 
performed in CH3CN at reflux under O2 atmosphere. [
e] 3-Unsubstituted 4-
iodomethyl-oxazolidin-2-one has been isolated in 54% yield (entry 4) and 43% 
yield (entry 5). [f] The reaction was carried out at room temperature using a 30% 
solution of H2O2 in water. [
g] In 3:1 ratio. [h] In 2:1 ratio. 
 
The result obtained with KI/H2O2 in water as solvent at room temperature prompted us to explore 
the substrate scope of the iodoamination reaction in the conditions of Table 1, entry 19. Initially, 
variously substituted alkenyl carbamates were envisaged and the results of the iodocyclization reactions 
are reported in Table 2. The presence of substituents on the allylic moiety is compatible with reaction 
conditions, as demonstrated by the formation of compounds 2b-h, although a mild heating in some cases 
was required. Compounds 2b and 2c were obtained as a mixture of cis/trans diastereoisomers, easily 
separated and fully characterized. 
The (R*,R*)-configuration of a representative iodo-derivative arising from O-allyl-carbamates 
mono-substituted at terminal position was confirmed by X-ray analysis of compound 2f (Figure 2), 
achieved by iodocyclization of the O-pent-2-enyl carbamate in the (Z)-configuration. The O-2-
cyclohexenyl-N-tosyl-carbamate furnished exclusively the bicyclic oxazolidinone 2i in 66% yield. The 
reaction conditions are also suitable for the iodoamination of O-alk-3-enyl carbamates, which provided 
the 1,3-oxazin-2-one products 2j and 2k.  
 
 
 
 
 
 
 
 
 
 Table 2. Reaction of iodoamination of alkenyl carbamates 
 
 
 
 
 
 
 
 
Figure 2. Molecular structure of the (R,R) enantiomer of 2f at room temperature, as derived from single 
crystal X-ray diffraction. The methyl of the tosyl group is rotationally disordered with site occupation 
factors of 0.64(7) and 0.36(7). Thermal ellipsoids are drawn at the 30% probability level. 
Configurational descriptors of the stereogenic centres are also shown. 
 
Interestingly, the treatment of the optically active carbamate 3 with H2O2 and KI in H2O/DMSO 
1:3 at 40 °C resulted selectively in an exo-cyclization, providing the spiro-compound 4 as the sole 
product (Scheme 2).  
[a] Starting from a mixture of (E/Z)-1e. [b] Starting from (Z)-1f. [c] Starting from (E)-1g. 
  
Scheme 2. Iodoamination of the optically active carbamate 3. 
 
 
Scheme 3. Selective formation of the sole diastereoisomer (-)-4. 
 
The stereoselective reaction path is due to the difference arisen from the torsional strain of the two 
plausible transition states having a substituent on the pseudo equatorial position (Scheme 3).[32-33] The 
stability of the chair-like transition state (from TS-A) rather than the twist-boat state (from TS-B) 
afforded only the trans-diaxial addition product (-)-4. 
 The configuration was unambiguously assigned by X-ray diffraction analysis (Figure 3).  
 
Figure 3. Molecular structure of 4 at room temperature, as derived from single crystal X-ray diffraction. 
Thermal ellipsoids are drawn at the 30% probability level. Configurational descriptors of the stereogenic 
centres are also shown. 
 
Based on the observed results and literature data,[10,11] a plausible mechanism for the iodocyclization is 
shown in Scheme 4 taking carbamate 1a as example. The I+ species generated in situ from KI and H2O2 
suggested the formation of the electrophilic iodinated intermediate A,[34-41] from which the anti-attack 
by the nucleophilic tosylamino group afforded the 4-iodomethyl oxazolidinone product.  
 
Scheme 4. Proposed iodoamination reaction mechanism 
 
The use of H2O2 and KI for the iodocyclization of N-allyl-N’-tosylureas resulted in a different outcome 
of the reaction depending on the substituent on the nitrogen atom. If the phenyl-substituted urea 5a 
provided the 4-iodomethyl-imidazolidinone 6a as the major product, the N-allyl-N-methyl-urea 5b 
followed mainly a iodoalkoxylation process giving the 2-imino-oxazolidine 6b in 52% yield (Scheme 
5). In both cases, minor products were detected in the crude mixtures, specifically arising from 
iodoalkoxylation (imino-oxazolidine 7a from 5a) and iodoamination (imidazolidinone 7b from 5b) 
reactions. The possibility of C-O vs C-N bond formation in intramolecular reactions of secondary ureas 
is well known in literature.[42-44] However, the low selectivity achieved in cyclization of compounds 
 5a,b decreases the interest from the synthetic point of view for the application of this procedure to 
alkenyl ureas. 
 
  
Scheme 5. Iodoamination reactions of allyl ureas 
 
Further extension of the reaction scope was attempted taking into account other alkenyl sulphonamides. 
The iodomethyl-substituted heterocyclic products, obtained by reaction with KI and H2O2 using 
H2O/DMSO in a ratio depending on the solubility of the substrates, are collected in Table 3.  
 
Table 3. Reaction of iodoamination of alkenyl tosylamines 
 
 N-Allyl 2-tosylamino-benzamides, already used by our group for the synthesis of benzodiazepine 
scaffolds,[45] were proven compatible with the iodoamination process, giving the 2-iodomethyl-
substituted 1,2,3,4-tetrahydro-benzodiazepin-5-one derivatives 8a-d in 63-74% yield. Satisfyingly, this 
procedure also represents a valuable alternative for the synthesis of these compounds, previously 
reported in the literature by displacement with KI of the first-formed chloromethyl derivative.[46] The 
iodocyclization conditions were found effective also for the conversion of the 1-allyl-indole-2-N-
tosylcarboxamide into the iodomethyl-substituted pyrazino[1,2-a]indole 9. It is noteworthy the 
reluctance of these substrates to afford haloamination processes in palladium-catalyzed reactions,[47] as 
further proof of the fruitfulness of the KI/H2O2 system. Finally, we explored the behaviour of 2-allyl-
N-tosylanilines, already successfully undergone to iodoamination in palladium-catalyzed conditions.[21] 
Treatment of these substrates with the standard iodocyclization conditions provided the iodo-indolines 
10a-c, although in moderate yields.     
Conclusions 
In summary, we have developed an efficient iodoamination procedure on alkenes bearing a secondary 
sulphonamide group based on the use of KI/H2O2 system. The current methodology allows to achieve 
easily different kind of iodomethyl-substituted nitrogen containing heterocycles by totally selective exo-
cyclization which involves halogenation and the formation of an intramolecular C-N bond. This 
iodoamination reaction proceeds smoothly in water needing the minimum amount of DMSO as co-
solvent to solubilize the substrates. 
Experimental Section 
Analytical Instruments 
Melting points were determined in a Stuart Scientific melting point apparatus in open capillary tubes 
and are uncorrected. Chemicals were obtained from Sigma Aldrich and used without further purification. 
HPLC analyses were carried out on a Kromasil 5-AmyCoat column (4.6 mm i.d. × 250 mm, 5 μm, 
AkzoNobel). ESI mass spectra were recorded on a LCQ Advantage spectrometer from Thermo 
Finningan and a LCQ Fleet spectrometer from Thermo Scientific. The NMR spectroscopic experiments 
were carried out either on a Bruker AVANCE 400 (400 and 101 MHz for 1H and 13C, respectively), on 
a Varian OXFORD 300 MHz (300 and 75 MHz for 1H and 13C, respectively), or on a Bruker Avance 
300 MHz spectrometers (300 and 75 MHz for 1H and 13C, respectively). Optical rotations were 
measured on a Perkin–Elmer 343 polarimeter at 20 °C (concentration in g/100 mL). Chemical shifts δ 
are given in ppm relative to the CHCl3 internal standard, and the coupling constants J are reported in 
Hertz (Hz). 
 
 General Procedure for the Aminoiodination Reaction. To a solution of the appropriate olefins (1 equiv.) 
in a mixture of DMSO and water (0.1M), potassium iodide (2 equiv.) was added at room temperature, 
followed by the addition of a solution of 30% H2O2 (1.1 equiv) in water. The reaction was monitored 
by TLC. Then, the reaction mixture was quenched with Na2S2O3 (1M), and ethyl acetate was added. The 
organic layer was separated and washed with brine (6 x 15 mL). Afterwards, the organic phase was 
dried over Na2SO4, filtered and evaporated under reduced pressure. The purification by flash silica gel 
column chromatography afforded the corresponding products.  
 
4-(Iodomethyl)-3-tosyloxazolidin-2-one (2a). Compound 2a was prepared according to the general 
procedure (H2O/DMSO 3:1, 30h, room temperature) and isolated as white solid (yield 78%) after flash 
column chromatography (hexane:EtOAc 3:1). 1H NMR (400 MHz, CDCl3) δ 7.90 (d, J = 8.2 Hz, 2H), 
7.30 (d, J = 8.1 Hz, 2H), 4.54-4.44 (m, 1H), 4.36 (t, J = 8.8 Hz, 1H), 4.09 (dd, J = 9.1, 3.9 Hz, 1H), 3.60 
(dd, J = 10.3, 2.3 Hz, 1H), 3.49-3.28 (m, 1H), 2.39 (s, 3H). The data are in good agreement with those 
reported in the literature.[20]  
 
Cis-4-(Iodomethyl)-5-methyl-3-tosyloxazolidin-2-one (cis-2b). Compound cis-2b was prepared 
according to the general procedure (H2O/DMSO 2.5:1, 30h, room temperature) and isolated as white 
solid (yield 45%) after flash column chromatography (hexane:EtOAc 2:1). IR: 3428, 2975, 1778, 1359, 
1163, 1135, 819, 666, 594, 572, 541 cm-1. 1H NMR (300 MHz, CDCl3) δ 8.00 (d, J = 8.4 Hz, 2H), 7.39 
(d, J = 8.1 Hz, 2H), 4.91-4.79 (m, 1H), 4.54 (td, J = 7.2, 2.2 Hz, 1H), 3.58-3.40 (m, 2H), 2.48 (s, 3H), 
1.61 (d, J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 151.2 (s), 145.9 (s), 134. 7 (s), 129.9 (d), 128.7 
(d), 75.0 (d), 59.3 (d), 21.8 (q), 13.5 (q), -0.5 (t). MS: (ESI) m/z 418.05 [M+Na+]. Anal. calcd for 
C12H14NIO4S: C, 36.47; H, 3.57; N, 3.54. Found: C, 36.69; H, 3.32; N, 3.77. 
 
Trans-4-(Iodomethyl)-5-methyl-3-tosyloxazolidin-2-one (trans-2b). Compound trans-2b was 
prepared according to the general procedure (H2O/DMSO 2.5:1, 30h, room temperature) and isolated 
as white solid (yield 22%) after flash column chromatography (hexane:EtOAc 2:1). M.p. 146-147 °C. 
IR:  3435, 2984, 1785, 1595, 1359, 1166, 1131 1088, 816, 665, 596, 568, 539 cm-1. 1H NMR (400 MHz, 
CDCl3) δ 7.89 (d, J = 8.2 Hz, 2H), 7.30 (d, J = 8.1 Hz, 2H), 4.36 (dd, J = 6.3, 3.0 Hz, 1H), 4.02 (dt, J = 
8.9, 2.7 Hz, 1H), 3.57 (dd, J = 10.3, 2.6 Hz, 1H), 3.31 (t, J = 9.7 Hz, 1H), 2.39 (s, 3H), 1.31 (d, J = 6.3 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 148.0 (s), 145.0 (s), 134.6 (s), 129.9 (d), 128.5 (d), 77.3 (d), 
62.8 (d), 21.7 (q), 21.1 (q), 6.5 (t). MS: (ESI) m/z 418.12 [M+Na+]. Anal. calcd for C12H14NIO4S: C, 
36.47; H, 3.57; N, 3.54. Found: C, 36.31; H, 3.80; N, 3.72. 
 
 Cis-4-(Iodomethyl)-5-propyl-3-tosyloxazolidin-2-one (cis-2c). Compound cis-2c was prepared 
according to the general procedure (H2O/DMSO 1:1, 24h, 40 °C) and isolated as white solid (yield 28%) 
after flash column chromatography (hexane:EtOAc 5:1 to 2:1). M.p.: 130-131° C. IR: 3435, 2973, 1788, 
1366, 1160, 657, 560 cm-1. 1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 8.3 Hz, 2H), 7.38 (d, J = 8.2 Hz, 
2H), 4.70-4.54 (m, 1H), 4.55-4.39 (m, 1H), 3.51-3.40 (m, 2H), 2.39 (s, 3H), 2.04-1.98 (m, 1H), 1.85-
1.79 (m, 1H), 1.80-1.46 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 151.4 (s), 
145.0 (s), 135.0 (s), 130.0 (d), 128.9 (d), 78.8 (d), 59.1 (d), 29.6 (t), 21.9 (q), 19.3 (t), 13.8 (q), -0.0 (t). 
MS: (ESI) m/z 424.82 [M+], 446.54 [M+Na+]. Anal. calcd for C14H18NIO4S: C, 39.73; H, 4.29; N, 3.31. 
Found: C, 39.65; H, 4.08; N, 3.59. 
 
Trans-4-(Iodomethyl)-5-propyl-3-tosyloxazolidin-2-one (trans-2c). Compound trans-2c was 
prepared according to the general procedure (H2O/DMSO 1:1, 24h, 40 °C) and isolated as white solid 
(yield 32%) after flash column chromatography hexane:EtOAc 5:1 to 2:1). M.p. 118-119 °C. IR:  3437, 
2969, 1786, 1361, 1158, 655, 563 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.97 (d, J = 8.4 Hz, 2H), 7.39 (d, 
J = 8.2 Hz, 2H), 4.39-4.24 (m, 1H), 4.15 (dt, J = 8.8, 2.8 Hz, 1H), 3.64 (dd, J = 10.3, 2.8 Hz, 1H), 3.42 
(dd, J = 10.2, 8.8 Hz, 1H), 2.48 (s, 3H), 1.74-1.27 (m, 4H), 0.95 (t, J = 7.3 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 145.93 (s), 134.6 (s), 129.9 (d), 128.5 (d), 80.4 (d), 61.2 (d), 36.0 (t), 21.7 (q), 17.3 (d), 13.5 
(q), 7.0 (t). MS: (ESI) m/z 424.82 [M+], 446.54 [M+Na+]. Anal. calcd for C14H18NIO4S: C, 39.73; H, 
4.29; N, 3.31. Found: C, 39.46; H, 4.55; N, 3.04. 
 
4-(Iodomethyl)-5,5-dimethyl-3-tosyloxazolidin-2-one (2d). Compound 2d was prepared according to 
the general procedure (H2O/DMSO 2:1, 30h, room temperature) and isolated as white solid (yield 56%) 
after flash chromatography (hexane:EtOAc 3:1). 1H NMR (300 MHz, CDCl3) δ 7.98 (d, J = 8.3 Hz, 2H), 
7.37 (d, J = 8.1 Hz, 2H), 4.17 (dd, J = 7.6, 1.9 Hz, 1H), 3.59-3.41 (m, 2H), 2.46 (s, 3H), 1.61 (s, 3H), 
1.39 (s, 3H). The data are in good agreement with those reported in the literature.[24] 
 
4-(1-Iodopropyl)-3-tosyloxazolidin-2-one (2e). Compound 2e was prepared according to the general 
procedure (H2O/DMSO 2.5:1, 30h, room temperature) and isolated as white solid (yield 67%) after flash 
column chromatography (hexane:EtOAc 2:1). M.p. 164-165 °C. IR: 2998, 1781, 1602, 1346, 1174, 
1126 1075, 810, 603, 575, 549 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 8.2 Hz, 2H), 7.30 (d, J 
= 8.1 Hz, 2H), 4.81-4.62 (m, 1H), 4.33 (t, J = 9.0 Hz, 1H), 4.14 (dd, J = 9.0, 3.7 Hz, 1H), 3.90 (dq, J = 
6.6, 3.1 Hz, 1H), 2.39 (s, 3H), 1.77 (d, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 151.6 (s), 145.9 
(s), 134.6 (s), 129.8 (d), 128.8 (d), 66.4 (t), 61.2 (d), 29.2 (d), 23.1 (q), 21.7 (q). MS: (ESI) m/z 418.26 
[M+Na+]. Anal. calcd for C12H14NIO4S: C, 36.47; H, 3.57; N, 3.54. Found: C, 36.61; H, 3.30; N, 3.69. 
 
 4-(1-Iodopropyl)-3-tosyloxazolidin-2-one (2f). Compound 2f was prepared according to the general 
procedure (H2O/DMSO 2:1, 30h, room temperature) and isolated as white solid (yield 66%) after flash 
column chromatography (hexane:EtOAc 1:1). M.p. 146-146 °C. IR: 3435, 2971, 2873, 2850, 1784, 
1369, 1356, 1175, 1164, 1116, 668, 596, 540 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.97 (d, J = 7.9 Hz, 
2H), 7.40 (d, J = 7.9 Hz, 2H), 5.02-4.95 (m, 1H), 4.60-4.50 (m, 1H), 4.48-4.36 (m, 2H), 2.48 (s, 3H), 
1.62-1.45 (m, 2H), 1.01 (t, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 152.6 (s), 146.5 (s), 134.8 
(s), 130.3 (d), 128.7 (d), 66.8 (t), 61.0 (d), 37.5 (d), 24.1 (t), 22.1 (q), 14.6 (q). MS: (ESI) m/z 432.38 
[M+Na+]. Anal. calcd for C13H16NIO4S: C, 38.15; H, 3.94; N, 3.42. Found: C, 37.98; H, 4.17; N, 3.15. 
 
4-(1-Iodobutyl)-3-tosyloxazolidin-2-one (2g). Compound 2g was prepared according to the general 
procedure (H2O/DMSO 1:1, 24h, 40 °C) and isolated as white solid (yield 64%) after flash column 
chromatography (hexane:EtOAc 4:1). M.p. 136-137 °C. IR:  3439, 2965, 1784, 1352, 1121, 645, 565 
cm-1. 1H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 8.2 Hz, 2H), 7.30 (d, J = 8.1 Hz, 2H), 4.73-4.56 (m, 
1H), 4.32 (t, J = 9.0 Hz, 1H), 4.16 (dd, J = 9.0, 3.8 Hz, 1H), 4.09-3.98 (m, 1H), 2.39 (s, 3H), 1.73-1.28 
(m, 4H), 0.91 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 151.6 (s), 145.8 (s), 134.6 (s), 129.7 
(d), 128.8 (d), 66.6 (t), 60.1 (d), 38.6 (d), 37.3 (t), 22.7 (t), 21.7 (q), 13.1 (q). MS: (ESI) m/z 446.21 
[M+Na+]. Anal. calcd for C14H18NIO4S: C, 39.73; H, 4.29; N, 3.31. Found: C, 39.56; H, 4.47; N, 3.06. 
 
4-(2-Iodopropan-2-yl)-3-tosyloxazolidin-2-one (2h). Compound 2h was prepared according to the 
general procedure (H2O/DMSO 1:2, 30h, room temperature) and isolated as white solid (yield 55%) 
after flash chromatography (hexane:EtOAc 2.5:1). M.p. 156-160 °C (decomp.). IR: 3396, 2921, 1783, 
1165, 1160, 665, 554, 538 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.95 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 
8.3 Hz, 2H), 4.79 (dd, J = 8.0, 1.6 Hz, 1H), 4.63 (dd, J = 9.9, 1.6 Hz, 1H), 4.38 (dd, J = 9.7, 7.9 Hz, 
1H), 2.48 (s, 3H), 2.16 (s, 3H), 1.89 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 153.2, 145.9, 134.7, 129.8, 
128.5, 69.8, 67.0, 48.9, 35.4, 30.0, 21.7. MS: (ESI) m/z 432,24 [M+Na+]. Anal. calcd for C13H16NIO4S: 
C, 38.15; H, 3.94; N, 3.42. Found: C, 38.21; H, 3.72; N, 3.59. 
 
4-Iodo-3-tosylhexahydrobenzo[d]oxazol-2(3H)-one (2i). Compound 2i was prepared according to the 
general procedure (H2O/DMSO 1:1.5, 30h, room temperature) and isolated as white solid (yield 66%) 
after flash chromatography (hexane:EtOAc 3:1). M.p.: 171-172 °C. IR: 3294, 2940, 1787, 1175, 1163, 
671, 558, 541 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.98 (d, J = 8.2 Hz, 2H), 7.39 (d, J = 8.1 Hz, 2H), 
5.00 (dd, J = 8.0, 3.9 Hz, 1H), 4.77 (dd, J = 11.1, 6.2 Hz, 1H), 4.67 (dd, J = 6.5, 3.6 Hz, 1H), 2.48 (s, 
3H), 2.28 – 1.58 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 145.9 (s), 129.8 (d), 128.6 (d), 74.2 (d), 63.3 
(d), 28.9 (t), 25.6 (d), 25.1 (t), 21.7 (q), 18.1 (t). MS: (ESI) m/z 444.32 [M+Na+]. Anal. calcd for 
C14H16NIO4S: C, 39.92; H, 3.83; N, 3.33. Found: C, 40.13; H, 3.55; N, 3.24. 
  
 4-(Iodomethyl)-3-tosyl-1,3-oxazinan-2-one (2j). Compound 2j was prepared according to the general 
procedure (H2O/DMSO 3:1, 30h, room temperature) and isolated as white solid (yield 74%) after flash 
chromatography (hexane:EtOAc 2:1). M.p.: 127-128 °C. IR: 3324, 1722, 1358, 1271, 1170, 1143, 669, 
612, 542, 533 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 8.2 Hz, 2H), 7.25 (d, J = 8.1 Hz, 2H), 
4.75-4.57 (m, 1H), 4.33-4.14 (m, 2H), 3.69 (dd, J = 10.1, 3.0 Hz, 1H), 3.24 (t, J = 10.6 Hz, 1H), 2.53-
2.42 (m, 1H), 2.36 (s, 3H), 2.22-2.06 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 148.0 (s), 145.4 (s), 135.2 
(s), 129.5 (d), 129.1 (d), 63.9 (t), 55.4 (d), 26.0 (t), 21.7 (q), 5.3 (t). MS: (ESI) m/z 418.51 [M+Na+]. 
Anal. calcd for C12H14NIO4S: C, 36.47; H, 3.57; N, 3.54. Found: C, 36.41; H, 3.75; N, 3.39. 
 
4-(Iodomethyl)-4-methyl-3-tosyl-1,3-oxazinan-2-one (2k). Compound 2k was prepared according to 
the general procedure (H2O/DMSO 1.5:1, 30h, room temperature) and isolated as colorless oil (yield 
68%) after flash chromatography (hexane:EtOAc 4:1). IR: 2936, 1755, 1342, 1176, 667, 562, 546 cm-
1.1H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 8.1 Hz, 2H), 7.30 (d, J = 8.2 Hz, 2H), 4.30 (d, J = 10.4 Hz, 
1H), 4.23-4.15 (m, 2H), 3.89 (d, J = 10.4 Hz, 1H), 2.57-2.45 (m, 1H), 2.42 (s, 3H), 2.11-1.96 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ 149.3, 144.9, 136.6, 129.4, 129.1, 64.0, 62.6, 38.3, 25.8, 21.6, 13.0. MS: 
(ESI) m/z 432.45 [M+Na+]. Anal. calcd for C13H16NIO4S: C, 38.15; H, 3.94; N, 3.42. Found: C, 37.99; 
H, 4.13; N, 3.53. 
 
 (5S,6R,8S)-6-Iodo-8-(prop-1-en-2-yl)-1-tosyl-3-oxa-1-azaspiro[4.5]decan-2-one (4). Compound 4 
was prepared according to the general procedure (H2O/DMSO 1:3, 24h, 40 °C) and isolated as white 
solid (yield 63%) after flash chromatography (hexane:EtOAc 3:1). M.p.: 160-164 °C (decomp.). IR: 
3358, 3261, 2959, 2922, 1785, 1188, 1168, 1084, 667, 562, 545 cm-1. 1H NMR (300 MHz, CDCl3) δ 
8.06 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 5.46 (dd, J = 13.6, 4.1 Hz, 1H), 5.17 (s, 1H), 5.01 (s, 
1H), 4.48 (d, J = 8.3 Hz, 1H), 4.31 (d, J = 8.7 Hz, 1H), 3.03 (td, J = 13.8, 3.2 Hz, 1H), 2.93-2.82 (m, 
1H), 2.46 (s, 3H), 2.33-1.99 (m, 4H), 1.83 (s, 3H), 1.71-1.56 (m, 1H). 13C NMR (300 MHz, CDCl3) δ 
151.0 (s), 145.5 (s), 143.1 (s), 135.1 (s), 129.7 (d), 129.2 (d), 112.7 (t), 71.5 (t), 70.0 (s), 40.5 (d), 39.2 
(t), 34.2 (d), 30.5 (t), 24.6 (t), 22.5 (q), 21.7 (q). MS: (ESI) m/z 498,23 [M]+. [α]D20: -17 (c: 0.1 in CHCl3). 
Anal. calcd for C18H22NIO4S: C, 45.48; H, 4.67; N, 2.95. Found: C, 45.44; H, 4.89; N, 3.11. 
 
4-(Iodomethyl)-1-phenyl-3-tosylimidazolidin-2-one (6a). Compound 6a was prepared according to 
the general procedure (H2O/DMSO 1:1, 30h, room temperature) and isolated as pale yellow solid (yield 
54%) after flash chromatography (hexane:EtOAc 2.5:1). M.p. 148-149 °C. IR: 3023, 2958, 1716, 1599, 
1504, 1359, 1170, 1131, 751, 666, 592, 554 cm-1. 1H NMR (300 MHz, CDCl3) δ 8.02 (d, J = 8.4 Hz, 
2H), 7.53-7.43 (m, 2H), 7.35 (t, J = 8.0 Hz, 4H), 7.14 (t, J = 7.4 Hz, 1H), 4.54 (tt, J = 8.8, 3.2 Hz, 1H), 
 4.09 (t, J = 9.4 Hz, 1H), 3.78 (dd, J = 10.2, 2.7 Hz, 1H), 3.68 (dd, J = 9.6, 3.7 Hz, 1H), 3.54 (dd, J = 
10.2, 8.4 Hz, 1H). 7.54-7.44 (m, 2H), 7.41-7.32 (m, 4H), 7.14 (t, J = 7.4 Hz, 1H), 4.72-4.41 (m, 1H), 
4.09 (t, J = 9.4 Hz, 1H), 3.73 (ddd, J = 29.8, 9.9, 3.2 Hz, 1H), 3.54 (dd, J = 10.2, 8.4 Hz, 1H), 2.46 (s, 
3H). 13C NMR (75 MHz, CDCl3) δ 151.1 (s), 145.2 (s), 137.9 (s), 135.5 (s), 129.7 (d), 129.0 (d), 128.5 
(d), 124.6 (d), 118.9 (d), 52.9 (d), 49.6 (t), 21.6 (q), 9.3 (t). MS: (ESI) m/z 479.20 [M+Na+]. Anal. calcd 
for C17H17N2IO3S: C, 44.75; H, 3.76; N, 6.14. Found: C, 44.97; H, 3.50; N, 5.88. 
 
(Z)-N-(5-(Iodomethyl)-3-methyloxazolidin-2-ylidene)-4-methylbenzenesulfonamide (6b). 
Compound 6b was prepared according to the general procedure (H2O/DMSO 2:1, 30h, room 
temperature) and isolated as white solid (yield 52%) after flash chromatography (hexane:EtOAc 1:1). 
M.p. 120-121 °C. IR: 2920, 1728, 1358, 1172, 1140, 666, 590 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.87 
(d, J = 8.3 Hz, 2H), 7.25 (d, J = 8.1 Hz, 2H), 5.00-4.55 (m, 1H), 3.79 (t, J = 9.2 Hz, 1H), 3.37-3.22 (m, 
3H), 2.96 (s, 3H), 2.41 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 157.6 (s), 142.8 (s), 140.3 (s), 129.4 (d), 
127.6 (d), 77.1 (d), 53.5 (t), 32.1 (q), 21.9 (q), 5.1 (t). MS: (ESI) m/z 417.22 [M+Na+]. Anal. calcd for 
C12H15N2IO3S: C, 36.56; H, 3.84; N, 7.11. Found: C, 36.29; H, 4.12; N, 6.91. 
 
2-(Iodomethyl)-4-methyl-1-tosyl-1,2,3,4-tetrahydro-5H-benzo[e][1,4]diazepin-5-one (8a). 
Compound 8a was prepared according to the general procedure (H2O/DMSO 1.5:1, 20h, 60 °C) and 
isolated as white solid (yield 71%) after flash chromatography (hexane:EtOAc 1.5:1). M.p. 156-156 °C. 
IR: 3074, 1670, 1382, 1157, 1145, 1049, 712, 667 cm-1. 1H NMR (300 MHz, CDCl3) δ 7.65 (d, J = 7.2 
Hz, 1H), 7.60-7.38 (m, 5H), 7.27 (d, J = 7.7 Hz, 2H), 4.72-4.33 (m, 1H), 3.75-3.45 (m, 2H), 3.28-2.93 
(m, 2H), 2.62 (s, 3H), 2.43 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 167.5 (s), 144.1 (s), 135.3 (s), 134.4 
(s), 133.6 (d), 132.3 (s), 131.9 (d), 130.1 (d), 129.9 (d), 129.5 (d), 127.1 (d), 61.5 (d), 52.8 (t), 34.2 (q), 
21.6 (q), 4.0 (t). MS: (ESI) m/z 471,22 [M+Na+]. Anal. calcd for C18H19N2IO3S: C, 45.97; H, 4.07; N, 
5.96. Found: C, 45.94; H, 4.23; N, 6.19. 
 
4-Cyclohexyl-2-(iodomethyl)-1-tosyl-1,2,3,4-tetrahydro-5H-benzo[e][1,4]diazepin-5-one (8b). 
Compound 8b was prepared according to the general procedure (H2O/DMSO 1:5, 30h, 50 °C) and 
isolated as white solid (yield 68%) after flash chromatography (hexane:EtOAc 7:3). M.p. = 158–159 °C. 
IR = 2924, 1640, 1347, 1157, 1139, 1055, 710, 662 cm-1. 1H NMR (400 MHz, CDCl3): δ 7.61 (d, J = 8 
Hz, 1H), 7.47-7.38 (m, 5H), 7.17 (d, J = 8 Hz, 2H), 4.16-4.09 (m, 1H), 3.84-3.78 (m, 1H), 3.69 (dd, J = 
15.5Hz, 4.5Hz, 1H), 3.53 (dd, J = 9.9 Hz, 3.7 Hz, 1H), 2.97 (t, J = 10.1 Hz, 1H), 2.73 (dd, J = 15.4, 
11.9 Hz, 1H), 2.34 (s, 3H), 1.74-0.81 (m, 10H). 13C NMR (101 MHz, CDCl3): δ 167.5 (s), 144.1 (s), 
135.7 (s), 135.1 (s), 132.9 (d), 132.3 (s), 131.6 (d), 130.5 (d), 129.7 (d), 129.2 (d), 127.7 (d), 64.0 (d), 
 53.0 (d), 45.6 (t), 30.4 (t), 30.1 (t), 25.7 (t), 25.3 (t), 25.3 (t), 21.5 (q), 4.0 (t). MS: (ESI) m/z 561.45 
[M+Na+]. Anal. calcd for C23H27N2IO3S: C, 51.30; H, 5.05; N, 5.20. Found: C, 51.07; H, 5.28; N, 4.97. 
 
2-(Iodomethyl)-4-phenyl-1-tosyl-1,2,3,4-tetrahydro-5H-benzo[e][1,4]diazepin-5-one (8c). 
Compound 8c was prepared according to the general procedure (H2O/DMSO 1:5, 30h, 50 °C) and 
isolated as white solid (yield 63%) after flash chromatography (hexane:EtOAc 4:1). M.p.: 87–88 °C. IR 
= 1653, 1398, 1350, 1170, 1087, 1050, 743, 717. 1H NMR (400MHz, CDCl3): δ 7.68 (d, J = 7.4 Hz, 
1H), 7.55-7.42 (m, 5H), 7.21-7.14 (m, 5H), 6.59 (d, J = 7.5 Hz, 2H), 4.46-4.40 (m, 1H), 4.02 (dd, J = 
15.1, 4.3Hz, 1H), 3.60-3.35 (m, 2H), 3.11 (t, J = 9.8 Hz, 1H), 2.33 (s, 3H). 13C NMR (101MHz, CDCl3): 
δ 157.3 (s), 144.3 (s), 141.4 (s), 135.9 (s), 134.8 (s), 133.4 (d), 132.5 (s), 132.0 (d), 130.5 (d), 130.0 (d), 
129.4 (d), 128.0 (d), 127.6 (d), 126.8 (d), 125.3 (d), 62.0 (d), 54.3 (t), 21.5 (q), 4.2 (t). MS: (ESI) m/z 
555.23 [M+Na+]. Anal. calcd for C23H21N2IO3S: C, 51.89; H, 3.98; N, 5.26. Found: C, 52.01; H, 3.81; 
N, 5.45. 
 
2-(Iodomethyl)-4-methyl-8-nitro-1-tosyl-1,2,3,4-tetrahydro-5H-benzo[e][1,4]diazepin-5-one (8d). 
Compound 8d was prepared according to the general procedure (H2O/DMSO 2:1, 24h, 60 °C) and 
isolated as pale yellow solid (yield 74%) after flash chromatography (hexane:EtOAc 1:1). M.p. 85-
86 °C. IR: 2921, 1654, 1334, 1155, 1111, 709, 666, 583, 571 cm-1. 1H NMR (300 MHz, CDCl3) δ 8.42 
(d, J = 2.1 Hz, 1H), 8.30 (dd, J = 8.5, 2.2 Hz, 1H), 7.81 (d, J = 8.5 Hz, 1H), 7.42 (d, J = 8.3 Hz, 2H), 
7.32-7.22 (m, 2H), 4.66-4.28 (m, 1H), 3.66-3.48 (m, 2H), 3.28-3.07 (m, 2H), 2.64 (s, 3H), 2.43 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 144.8 (s), 140.1 (s), 134.7 (s), 133.8 (s), 131.2 (d), 130.1 (d), 129.0 (d), 
127.1 (d), 123.9 (d), 61.3 (d), 52.8 (t), 34.3 (q), 21.6 (q), 4.1 (t).  MS: (ESI) m/z 538.43[M+Na+]. 
Anal. calcd for C18H18N3IO5S: C, 41.95; H, 3.52; N, 8.15. Found: C, 42.08; H, 3.43; N, 7.96. 
 
3-(Iodomethyl)-2-tosyl-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one (9). Compound 9 was prepared 
according to the general procedure (H2O/DMSO 1:5, 6h, room temperature) and isolated as white solid 
(yield 67%) after flash chromatography (hexane:EtOAc 4:1). M.p. 173-174 °C. IR: 3435, 2922, 1690, 
1536, 1346, 1163, 742, 715, 556 cm-1. 1H NMR (300 MHz, CDCl3) δ 8.06 (d, J = 8.4 Hz, 2H), 7.71 (d, 
J = 8.2 Hz, 1H), 7.46-7.33 (m, 5H), 7.26-7.13 (m, 1H), 5.37-5.25 (m, 1H), 5.13 (d, J = 13.2 Hz, 1H), 
4.33 (dd, J = 12.8, 3.0 Hz, 1H), 3.62-3.49 (m, 1H), 3.17 (dd, J = 11.6, 10.3 Hz, 1H), 2.46 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ 156.3 (s), 145.5 (s), 137.3 (s), 135.8 (s), 129.6 (d), 129.0 (d), 127.3 (s), 126.4 
(d), 126.1 (s), 123.2 (d), 121.6 (d), 110.0 (d), 56.9 (d), 42.8 (t), 21.7 (q), 2.8 (t). MS: (ESI) m/z 481.25 
[M+], 503.38 [M+Na+]. Anal. calcd for C19H17N2IO3S: C, 47.51; H, 3.57; N, 5.83. Found: C, 47.59; H, 
3.80; N, 5.62. 
 
 2-(Iodomethyl)-1-tosylindoline (10a). Compound 10a was prepared according to the general 
procedure (H2O/DMSO 1:1, 24h, 60 ° C) and isolated as pale yellow solid (yield 58%) after flash 
chromatography (hexane:EtOAc 10:1). 1H NMR (400 MHz, CDCl3) δ = 7.57 (d, J = 8.1 Hz, 1H), 7.48 
(d, J = 8.1 Hz, 2H), 7.20-7.07 (m, 3H), 7.00-6.93 (m, 2H), 4.30-4.24 (m, 1H), 3.58 (dd, J = 9.7, 3.4 Hz, 
1H), 3.18 (t, J = 9.9 Hz, 1H), 2.86 (dd, J = 16.7, 9.3 Hz, 1H), 2.76 (dd, J = 16.7, 3.0 Hz, 1H), 2.27 (s, 
3H). The data are in good agreement with those reported in the literature.[18] 
 
5-Chloro-2-(iodomethyl)-1-tosylindoline (10b). Compound 10b was prepared according to the 
general procedure (H2O/DMSO 1:1.2, 20h, 40 °C) and isolated as white solid (yield 62%) after flash 
chromatography (hexane:EtOAc 10:1). 1H NMR (300 MHz, CDCl3) δ = 7.58-7.53 (m, 3H), 7.23-7.16 
(m, 3H), 7.03 (s, 1H), 4.36 − 4.30 (m, 1H), 3.63 (dd, J = 9.7, 3.3 Hz, 1H), 3.26 (t, J = 9.9 Hz, 1H), 2.89-
2.82 (m, 2H), 2.37 (s, 3H). The data are in good agreement with those reported in the literature.[18] 
 
2-(Iodomethyl)-6,7-dimethyl-1-tosylindoline (10c). Compound 10c was prepared according to the 
general procedure (H2O/DMSO 1:2.5, 20h, 60 °C) and isolated as pale yellow solid (yield 51%) after 
flash chromatography (hexane:EtOAc 12:1). 1H NMR (300 MHz, CDCl3) δ 7.31 (d, J = 8.3 Hz, 2H), 
7.15 (d, J = 8.0 Hz, 2H), 6.96 (t, J = 6.9 Hz, 2H), 6.77 (d, J = 7.5 Hz, 1H), 4.48-4.37 (m, 1H), 3.36 (dd, 
J = 9.8, 5.1 Hz, 1H), 2.98 (t, J = 9.9 Hz, 1H), 2.45 (s, 3H), 2.38 (s, 3H), 2.31 (s, 3H), 2.12-1.98 (m, 2H). 
The data are in good agreement with those reported in the literature.[20]  
 
General procedure for the X-ray diffraction analysis.  Single-crystal X-ray diffraction experiments were 
carried out on a Bruker AXS three-circle diffractometer equipped with an Apex II CCD area detector. 
Data were collected using graphite-monochromated Mo K radiation (=0.71073 Å) at a nominal X-
rays power of 50 kV x 30 mA. A 100 % complete full sphere of reflections was recorded up to a 
maximum resolution of 0.77 Å, resulting in 3578 (compound 2f) and 4460 (ompound 4) independent 
structure factor amplitudes. The latter were reduced with the SAINT+ software[48] and corrected for 
absorption using the empirical procedure implemented in SADABS.[49] The structures were solved by 
either iterative charge-flipping methods  implemented in SUPERFLIP[50] (compound 2f) or by direct 
methods (SIR92).[51] Structure refinements were carried out in the independent atom approximation 
with the least squares algorithm implemented in shelxl.[52] Molecular drawings were plotted with 
Diamond 3.0k (©1997–2014 Crystal Impact GbR, Bonn, Germany).  
X-ray-quality crystals of the compound 2f (prismatic habit, colorless) were grown by slow evaporation 
( 10 hrs) from a 1:1 mixture of hexane and CH2Cl2 at room temperature. The specimen used for the X-
ray diffraction experiment was cut from a larger agglomerate and polished by mechanical ablation in a 
drop of perfluorinated oil. It showed pleochroism under polarized light (from colourless to dark grey). 
 2f is chiral and crystallizes in the monoclinic centric space group P21/n as a racemate, with one molecule 
per asymmetric unit and absolute configurations (S,S) or (R,R). The oxazolidin-2-one ring is slightly 
distorted toward a half-chair conformation. Unit cell (Å, deg, Å3), as estimated from 9987 intense 
reflections with 4.7  2  56.2 deg: a = 7.8801(2), b = 17.1890(5), c = 11.5884(3),  = 96.156(1), V =  
1560.6(1). 
X-ray quality crystals (prismatic habit, colorless) were grown by slow evaporation ( 6 hrs) from a 1:1 
hexane:CH2Cl2 mixture at room temperature. The sample chosen for the X-ray analysis was cut from a 
larger agglomerate and polished by mechanical ablation in a drop of perfluorinated oil. It showed 
pleochroism under polarized light (from colourless to dark grey). The compound is chiral and 
crystallizes in the orthorhombic acentric space group P212121 as a pure enantiomer, with one molecule 
per asymmetric unit. The presence of sulphur and iodine anomalous scatterers allow to secure the 
absolute molecular configuration, with a Flack parameter[53] as low as 0.02(2) by classical fit to all 
intensities (Figure 3). The saturated six-membered ring assumes an almost perfect chair conformation, 
while the oxazolidin-2-one ring, analogously to compound 2f, adopts a slightly distorted half-chair 
conformation. Unit cell (Å, Å3), as estimated from 8060 intense reflections with 5.3  2  47.2 deg: a 
= 8.1577(2), b = 11.8874(2), c = 20.0540(4), V =  1944.7(1). 
 
Acknowledgements  
Università degli Studi dell’Insubria and Università degli Studi di Milano are acknowledged for 
financial support.  
Author Contribution Statement  
G. B. and E. M. B. designed the project. S. G. and R. S. performed the experiments. XRD data was 
acquired and analyzed by L. L. P. All authors contributed to writing the manuscript. 
References 
[1] S. R. Chemler, M. T. Bovino, ‘Catalytic Aminohalogenation of Alkenes and Alkynes’, ACS Catal. 
2013, 3, 1076-1091.  
[2] C. K. Tan, Y. Y. Yeung, ‘Recent Advances in Stereoselective Bromofunctionalization 
of Alkenes using N-Bromoamide Reagents’, Chem. Commun. 2013, 49, 7985-7996. 
[3] E. M. G. Broggini, T. Borelli, S. Giofré A. Mazza, ‘Intramolecular Oxidative Palladium-Catalyzed 
Amination Involving Double C–H Functionalization of Unactivated Olefins’, Synthesis 2017, 49, 
2803- 2818.  
[4] G. Q. Liu, W. Li, Y. M. Li, ‘A New Method for Intramolecular Chloroamination of 
Unfunctionalized Olefins’, Adv. Synth. Catal. 2013, 355, 395-402. 
 [5] M. R. Manzoni, T. P. Zabawa, D. Khasi, S. R. Chemler, ‘Palladium(II)-Catalyzed Intramolecular 
Aminobromination and Aminochlorination of Olefins’, Organometallics 2004, 23, 5618-5621. 
[6] D. H. Horning, J. M. Muchowski, ‘Intramolecular Bromination. Part I’, Can. J. Chem. 1974, 52, 
1321- 1330. 
[7] W. Li, G.-Q. Liu, B. Cui, L. Zhang, T.-T. Li, L. Li, L. Duan, Y.-M. Li ‘Transition Metal-Free 
Iodine-Promoted Haloamination of Unfunctionalized Olefins’, RSC Adv. 2014, 4, 13509-13513. 
[8] J. Qiu, R. B. Silverman, ‘A New Class of Conformationally Rigid Analogues of 4-Amino-5-
halopentanoic Acids, Potent Inactivators of γ-Aminobutyric Acid Aminotransferase’, J. Med. Chem. 
2000, 43, 706-720. 
[9] K. Pors, S. D. Shnyder, P. H. Teesdale-Spittle, J. A. Hartley, M. Zloh, M. Searcey, L. H. Patterson, 
‘Synthesis of DNA-Directed Pyrrolidinyl and Piperidinyl Confined Alkylating 
Chloroalkylaminoanthraquinones: Potential for Development of Tumor-Selective N-Oxides’, J. 
Med. Chem. 2006, 49, 7013-7023.  
[10] A. F. French, S. Bissmire, T. Wirth, ‘Iodine Electrophiles in Stereoselective Reactions: Recent 
Developments and Synthetic Applications’, Chem. Soc. Rev. 2004, 33, 354-362. 
[11] P. Mizar, T. Wirth, ‘Iodoaminations of Alkenes’, Synthesis 2017, 49, 981-986. 
[12] O. Kitagawa, N. Kikuchi, T. Hanano, K. Aoki, T. Yamazaki, M. Okada, T. Taguchi, ‘A Mild and 
Highly Chemoselective α-Iodination of N-Allylic Carboxamides and Lactams’, J. Org.  Chem. 1995, 
60, 7161-7165. 
[13] M. Fujita, O. Kitagawa, T. Suzuki, T. Taguchi, ‘Regiocontrolled Iodoaminocyclization Reaction of 
an Ambident Nucleophile Mediated by Basic Metallic Reagent’, J. Org. Chem. 1997, 62, 7330-
7335. 
[14] O. Kitagawa, T. Suzuki, T. Taguchi, ‘t-BuOK-Mediated Iodoaziridination Reaction of N-Allylic 
Tosylamide Derivatives’, J. Org. Chem. 1998, 63, 4842-4845.  
[15] Y. Wang, K.-F. Wang, Y. Su, Z. Yang, L. Wen, L. Liu, J. Wang, D. Huang, Y. Hu, ‘Cascade 
Oxidation/Halogenoaminocyclization Reaction of Trifluoromethylated Homoallylic N-
Acylhydrazines: Metal-free Synthesis of CF3-Substituted Pyrazolines’, J. Org. Chem. 2018, 83, 
939-950. 
[16] S. Knapp, K. E. Rodriques, A. T. Levorse, R. M. Omaf, ‘A Procedure for “Iodolactamization”’, 
Tetrahedron Lett. 1985, 26, 1803-1806. 
[17] A. Bongini, G. Cardillo, M. Orena, S. Sandri, C. Tomasini, ‘Factors Affecting the Regioselection 
of Allylic Imidate Iodocyclization’, J. Org. Chem. 1986, 51, 4905-4910. 
 [18] C. S. Brindle, C. S. Yeung, E. N. Jacobsen, ‘Chiral β-Iodoamines by Urea-Catalysed 
Iodocyclization of Trichloroacetimidates’, Chem. Sci. 2013, 4, 2100-2104. 
 [19] G. Q. Liu, Y. M. Li, ‘Regioselective (Diacetoxyiodo)benzene-Promoted Halocyclization of 
Unfunctionalized Olefins’, J. Org. Chem. 2014, 79, 10094-10109. 
[20] M. T. Bovino, S. R. Chemler, ‘Catalytic Enantioselective Alkene Aminohalogenation/Cyclization 
Involving Atom Transfer’, Angew. Chem., Int. Ed. 2012, 51, 3923-3927. 
[21] L. Chen, X. Luo, Y. Li, ‘Palladium-Catalyzed Intramolecular Aminoiodination of Alkenes Using 
Molecular Oxygen as Oxidant’, Monatsh. Chem. 2017, 148, 957-961. 
[22] H. Sun, B. Cui, G.-Q. Liu, Y.-M. Li, ‘MnI2-Catalysed Regioselective Intramolecular Iodoamination 
of Unfunctionalized Olefins’, Tetrahedron 2016, 72, 7170-7178.  
[23] H. Sun, B. Cui, L. Duan, Y.-M. Li, ‘Intramolecular Aminoalkoxylation of Unfunctionalized Olefins 
via Intramolecular Iodoamination and Aziridinium Ion Ring-Opening Sequence’, Org. Lett. 2017, 
19, 1520-1523. 
[24] H. Liu, Y. Pan, C. Tan, ‘Sodium Nitrite (NaNO2) Catalysed Iodo-cyclisation of Alkenes and 
Alkynes using Molecular Oxygen’, Tetrahedron Lett. 2008, 49, 4424-4426. 
[25] M. Hashimoto, M. Matsumoto, K. Yamada, S. Terashima, ‘Synthetic Studies of Carzinophilin. Part 
4: Chemical and Biological Properties of Carzinophilin Analogues’, Tetrahedron 2003, 59, 3089-
3097. 
[26] I. Pérez-Castro, O. Caamaňo, F. Fernàndez, M.D. Garcìa, C. Lopez, E. De Clercq, ‘Synthesis of 4-
Substituted-1,2,3-triazole Carbanucleoside Analogues of Ribavirin via Click chemistry’, Org. 
Biomol. Chem. 2007, 5, 3805-3813. 
[27] S. Gazzola, E. M. Beccalli, T. Borelli, C. Castellano, D. Diamante, G. Broggini, ‘Selective 7-endo-
Cyclization of 3-Aza-5-alkenols through Oxidative Pd(II)-Catalyzed Olefin Oxyarylation’, Synlett 
2018, 29, 503-508. 
[28] G. Broggini, E. M. Beccalli, T. Borelli, F. Brusa, S. Gazzola, A. Mazza, ‘Intra-Intermolecular 
Palladium-Catalyzed Domino Reactions of Glycine Allylamides for the Synthesis of Diversely 
Functionalized Piperazinones’, Eur. J. Org. Chem. 2015, 4261-4268.  
[29] G. Broggini, V. Barbera, E. M. Beccalli, U. Chiacchio, A. Fasana, S. Galli, S. Gazzola, ‘Selective 
Intramolecular Palladium(II)‐Catalyzed Aminooxygenation vs. Diamination of Alkenylureas: 
Efficient Microwave‐Assisted Reactions to Bicyclic Piperazinones’, Adv. Synth. Catal. 2013, 355, 
1640-1648. 
[30] E. Borsini, G. Broggini, A. Fasana, S. Galli, M. Khansaa, U. Piarulli, M. Rigamonti, 
‘Intramolecular Palladium‐Catalyzed Aminocarboxylation of Olefins as a Direct Route to Bicyclic 
Oxazolidinones’, Adv. Synth. Catal. 2011, 353, 985-994. 
[31]  T. Froehr, C. P. Sindlinger, U. Kloeckner, P. Finkbeiner, B. J. Nachtsheim, ‘Benzoxazoles – 
The First Example of an Iodide-Catalyzed Oxidative Amination of Heteroarenes’, Org. Lett. 2011, 
13, 3754-3757. 
  [32] A. Fürst, P. A. Plattner, ‘2α, 3α‐ und 2β, 3β‐Oxido‐chlolestane; Konfiguration der 2‐Oxy‐
cholestane’ Helv. Chim. Acta 1949, 32, 275-283. 
[33] G. Bellucci, G. Berti, G. Ingrosso, A. Vatteroni, G. Conti, R. Ambrosetti, ‘Influence of Substituents 
in the 3-Position of Cyclohexene Oxides on the Rates of their Reactions with Hydrogen Chloride 
in Low Polarity Aprotic Solvents’, J. Chem. Soc., Perkin Trans. 2 1978, 627-632.  
[34] G. Li, L. Huang, J. Xu, W. Sun, J. Xie, L. Hong, R. Wang, ‘Sodium Iodide/Hydrogen Peroxide-
Mediated Oxidation/Lactonization for the Construction of Spirocyclic Oxindole-Lactones’, Adv. 
Synth. Catal. 2016, 358, 2873-2877. 
[35] A. Yoshimura, C. Zhu, K. R. Middleton, A. D. Todora, B. J. Kastern, A. V. Maskaev, V. V. 
Zhdankin, ‘Hypoiodite Mediated Synthesis of Isoxazolines from Aldoximes and Alkenes Using 
Catalytic KI and Oxone as the Terminal Oxidant’, Chem. Commun. 2013 49, 4800-4802. 
[36] V. K. Yadav, V. P. Srivastava, L. D. S. Yadav, ‘ Iodide Catalyzed Synthesis of 2-
Aminobenzoxazoles via Oxidative Cyclodesulfurization of Phenolic Thioureas with Hydrogen 
Peroxide’, Tetrahedron Lett. 2018, 59, 252-255. 
[37] M. Uyanik, H. Okamoto, T. Yasui, K. Ishihara, ‘Quaternary Ammonium (Hypo)iodite Catalysis for 
Enantioselective Oxidative Cycloetherification’, Science 2010, 328, 1376-1379. 
[38] C. Fortin, S. Khanniche, D. Khiri, V. Fèvre-Nollet, P. Lebègue, F. Cousin, I. Černušàk, F. Louis, 
‘Reactivity of Hydrogen Peroxide with Br and I Atoms’, J. Phys. Chem. 2018, 122, 1053-1063. 
[39] T. K. Achar, S. Maiti, P. Mal, ‘PIDA-I2 Mediated Direct Vicinal Difunctionalization of Olefins: 
Iodoazidazion, iodoetherification and iodoacyloxylation’, Org. Biomol. Chem. 2016, 14, 4654. 
[40] K. B. Hong, J. N. Johnston, ‘Alkene Diamination Using Electron-Rich Amines: Hypervalent 
Iodine-Promoted Inter/Intramolecular C-N Bond Formation’, Org. Lett. 2014, 16, 3804-3807. 
[41] Y.-T. Gao, X.-Y. Jin, Q. Liu, A.-D. Liu, L. Cheng, D. Wang, ‘Iodide/H2O2 Catalyzed 
Intramolecular Oxidative Amination for the Synthesis of 3,2’-Pyrrolidinyl Spirooxindoles’, 
Molecules 2018, 23, 2265. 
[42] S. Gazzola, E. M. Beccalli, T. Borelli, C. Castellano, M. A. Chiacchio, D. Diamante, G. Broggini, 
‘Copper(II)-Catalyzed Alkoxyhalogenation of Alkynyl Ureas and Amides as a Route to 
Haloalkylidene-Substituted Heterocycles’, J. Org. Chem. 2015, 80, 7226-7234. 
[43] K. Muniz, A. Iglesias, Y. Fang, ‘Platinum-Catalysed Aerobic 1,2-Aminooxygenation of Alkenes’, 
Chem. Commun. 2009, 5591-5593. 
[44] A. Gimeno, A. B. Cuenca, M. Médio-Simon, G. Asensio, ‘Gold(I)‐Catalyzed Reactions of 1‐(ortho‐
Alkynylaryl)ureas: Highly Selective Heterocyclization and Synthesis of Mixed N,O‐Acetals’, Adv. 
Synth, Catal. 2014, 356, 229-236. 
 [45] E. M. Beccalli, G. Broggini, G. Paladino, A. Penoni, C. Zoni, Regioselective Formation of Six- and 
Seven-Membered Ring by Intramolecular Pd-Catalyzed Amination of N-Allyl-anthranilamides, J. 
Org. Chem. 2004, 69, 5627-5630.  
[46] A. D. Manick, F. Berhal, G. Prestat, ‘Synthesis of Six- and Seven-Membered Chloromethyl-
Substituted Heterocycles via Palladium-Catalyzed Amino- and Oxychlorination’, Synthesis 2016, 
48, 3719-3729. 
[47]  G. Abbiati, E. M. Beccalli, G. Broggini, M. Martinelli, G. Paladino, ‘Pd-Catalyzed Cyclization of 
1-Allyl-2-indolecarboxamides by Intramolecular Amidation of Unactivated Ethylenic Bond’, 
Synlett 2006, 73-76. 
[48] Bruker AXS Inc., SAINT+, Madison, Wisconsin, USA, 2012. 
[49] Bruker AXS Inc., SADABS, Madison, Wisconsin, USA, 2001. 
[50] L. Palatinus, G. Chapuis, ‘SUPERFLIP – A Computer Program for the Solution of Crystal 
Structures by Charge Flipping in Arbitrary Dimensions’, J. Appl. Crystallogr. 2007, 40, 786-790. 
[51] A. Altomare, G. Cascarano, C. Giacovazzo, A. Guagliardi, ‘Completion and Refinement of Crystal 
Structures with SIR92’, J. Appl. Crystallogr. 1993, 26, 343-350. 
[52] G. M. Sheldrick, ‘SHELXT – Integrated Space-group and Crystal-structure Determination’, Acta 
Crystallogr. 2015, 71, 3-8. 
[53] H. D. Flack., ‘On Enantiomorph-polarity Estimation’, Acta Crystallogr. 1983, A39, 876-881. 
